Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Avid Bioservices Inc

Healthcare US CDMO

NoneUSD
0.00(0%)

Last update at 2025-03-03T19:00:46.376208Z

Day Range

--
LowHigh

52 Week Range

4.6612.48
LowHigh

Fundamentals

  • Previous Close 12.49
  • Market Cap784.74M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-7.68700M
  • Revenue TTM142.36M
  • Revenue Per Share TTM2.25
  • Gross Profit TTM 31.48M
  • Diluted EPS TTM-2.29

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-04-30 2022-04-30 2021-04-30 2020-04-30 2019-04-30
Type yearly yearly yearly yearly yearly
Date 2023-04-30 2022-04-30 2021-04-30 2020-04-30 2019-04-30
Income before tax 2.00M 12.66M 11.21M -10.46600M -5.34000M
Minority interest - - - - -
Net income 0.56M 127.67M 11.21M -7.25600M -4.21500M
Selling general administrative 27.88M 21.23M 17.06M 14.52M 12.85M
Selling and marketing expenses - - - - -
Gross profit 31.48M 36.65M 29.31M 3.93M 7.22M
Reconciled depreciation 7.21M 4.48M 3.45M 3.09M 2.75M
Ebit -2.60700M 10.86M 8.92M -10.58500M -8.36800M
Ebitda 4.60M 15.34M 12.38M -10.23000M -5.62200M
Depreciation and amortization 7.21M 4.48M 3.45M 0.35M 2.75M
Non operating income net other 1.00M -0.08100M 0.13M 0.47M 0.28M
Operating income -2.60700M 10.86M 8.92M -10.58500M -5.62200M
Other operating expenses 145.66M 104.17M 83.62M 70.29M 59.23M
Interest expense 2.60M 2.68M 1.16M 0.47M 3.87M
Tax provision 1.44M -115.01100M 0.00000M 0.00000M -0.28400M
Interest income - - 0.13M 0.47M 0.28M
Net interest income -2.60000M -2.68000M -1.03100M 0.47M 0.28M
Extraordinary items - - - - 0.84M
Non recurring - - - - -
Other items - - - - -
Income tax expense 1.44M -115.01100M -2.28900M -3.21000M -0.28400M
Total revenue 149.27M 119.60M 95.87M 59.70M 53.60M
Total operating expenses 27.88M 21.23M 17.06M 14.52M 12.85M
Cost of revenue 117.79M 82.95M 66.56M 55.77M 46.38M
Total other income expense net 4.61M 1.80M 2.29M 0.12M 0.28M
Discontinued operations - - - - 0.84M
Net income from continuing ops 0.56M 127.67M 11.21M -10.46600M -5.05600M
Net income applicable to common shares 0.56M 127.67M 3.32M -15.15200M -8.90100M
Preferred stock and other adjustments - - 7.89M 4.69M 4.69M
Breakdown 2024-04-30 2023-04-30 2022-04-30 2021-04-30 2020-04-30
Type yearly yearly yearly yearly yearly
Date 2024-04-30 2023-04-30 2022-04-30 2021-04-30 2020-04-30
Total assets 336.56M 451.05M 429.84M 265.51M 107.62M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 6.51M 2.09M 1.88M 1.06M 0.71M
Total liab 275.67M 261.58M 255.32M 187.77M 65.72M
Total stockholder equity 60.89M 189.47M 174.53M 77.74M 41.90M
Deferred long term liab - - 3.50M 0.90M -
Other current liab 8.66M 10.41M 9.49M 9.55M 3.83M
Common stock 0.06M 0.06M 0.06M 0.06M 0.06M
Capital stock 0.06M 0.06M 0.06M 0.06M 0.06M
Retained earnings -571.87100M -430.81700M -431.37700M -559.85900M -571.07100M
Other liab - - - - -
Good will - - - - -
Other assets - 118.46M 120.06M 1.56M 0.65M
Cash 38.11M 38.54M 126.17M 169.91M 36.26M
Cash and equivalents - - - - -
Total current liabilities 70.57M 73.71M 75.76M 70.94M 44.48M
Current deferred revenue 39.89M 37.35M 53.80M 50.77M 29.12M
Net debt 169.73M 150.69M 56.36M -51.72200M -9.41100M
Short term debt 2.80M 1.36M 2.97M 1.35M 5.61M
Short long term debt - - - - 4.38M
Short long term debt total 207.83M 189.23M 182.53M 118.19M 26.85M
Other stockholder equity 632.70M 620.22M 605.84M 637.53M 612.91M
Property plant equipment - 177.37M 92.95M 37.45M 27.11M
Total current assets 104.00M 112.45M 180.02M 207.80M 59.76M
Long term investments - - - - -
Net tangible assets - 189.47M 174.53M 77.74M 41.89M
Short term investments 4.40M - - - -
Net receivables 29.01M 27.91M 25.92M 24.95M 11.91M
Long term debt 153.59M 140.62M 139.58M 96.95M -
Inventory 30.38M 43.91M 26.06M 11.87M 10.88M
Accounts payable 20.67M 24.59M 9.50M 9.26M 5.93M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -17.64100M
Additional paid in capital - - - - -
Common stock total equity - 0.06M 0.06M 0.06M 0.06M
Preferred stock total equity - - - - 0.00200M
Retained earnings total equity - -430.81700M -431.37700M -559.85900M -571.07100M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 4.88M 4.82M 4.98M 1.56M 0.65M
Deferred long term asset charges - - - - -
Non current assets total 232.56M 338.60M 249.82M 57.71M 47.86M
Capital lease obligations 52.79M 48.61M 42.95M 21.24M 22.47M
Long term debt total - 140.62M 139.58M 96.95M -
Breakdown 2023-04-30 2022-04-30 2021-04-30 2020-04-30 2019-04-30
Type yearly yearly yearly yearly yearly
Date 2023-04-30 2022-04-30 2021-04-30 2020-04-30 2019-04-30
Investments -77.63800M -56.41100M -9.86400M -3.81200M 4.54M
Change to liabilities 2.08M -0.04000M 5.39M 0.76M 2.46M
Total cashflows from investing activities -77.63800M -56.41100M -9.86400M -3.81200M 4.54M
Net borrowings -0.50500M -0.16200M 133.99M 4.30M -0.07400M
Total cash from financing activities 2.90M 3.20M 112.33M 1.10M -2.86300M
Change to operating activities 1.06M -3.32900M 4.74M -0.05000M 0.31M
Net income 0.56M 127.67M 11.21M -10.46600M -4.21500M
Change in cash -87.62400M -43.74900M 133.65M 3.11M -9.91400M
Begin period cash flow 126.52M 170.26M 36.61M 33.50M 43.41M
End period cash flow 38.89M 126.52M 170.26M 36.61M 33.50M
Total cash from operating activities -12.88700M 9.46M 31.18M 5.83M -11.59500M
Issuance of capital stock 0.00000M 0.00000M 32.14M 4.38M 0.00000M
Depreciation 7.21M 4.48M 3.45M 3.09M 2.75M
Other cashflows from investing activities - - - - 6.05M
Dividends paid 0.00000M 0.00000M -4.45500M -4.32500M 4.33M
Change to inventory -17.84600M -14.19100M -0.98800M -4.32600M 1.70M
Change to account receivables 2.25M -1.70500M -10.23600M -1.23200M -3.62000M
Sale purchase of stock 3.41M 3.36M -40.49000M 0.19M 0.26M
Other cashflows from financing activities 3.41M 3.36M 125.23M 5.50M 1.54M
Change to netincome 12.56M -107.32100M 3.85M 2.51M -3.82800M
Capital expenditures 77.64M 56.41M 9.86M 3.81M 1.50M
Change receivables 2.25M -1.70500M -10.23600M -1.23200M -3.62000M
Cash flows other operating -20.74700M -0.46000M 17.58M 15.49M -6.83800M
Exchange rate changes - - - - -
Cash and cash equivalents changes -87.62400M -43.74900M 133.65M 3.11M -9.91400M
Change in working capital -34.26300M -16.39600M 11.75M 10.69M -10.84800M
Stock based compensation 10.98M 7.38M 3.85M 2.50M 1.59M
Other non cash items 1.19M 1.41M 0.92M 0.01M -0.87300M
Free cash flow -90.52500M -46.94600M 21.32M 2.02M -13.09700M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CDMO
Avid Bioservices Inc		 - -% - - 88.50 5.53 13.38 6.72 107.87
NVO
Novo Nordisk A/S		 0.03 0.05% 47.45 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 46.84 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 8.43 1.80% 476.85 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 7.92 1.28% 625.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Avid Bioservices, Inc. operates as a contract development and manufacturing organization for the biotechnology and biopharmaceutical industries in the United States. It provides process development and current good manufacturing practice clinical and commercial manufacturing services of biologics, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, regulatory submission and support, upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization services. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is based in Tustin, California.

Avid Bioservices Inc

14191 Myford Road, Tustin, CA, United States, 92780

Key Executives

Name Title Year Born
Mr. Nicholas Stewart Green B.Sc., MBA Pres, CEO & Director 1965
Mr. Daniel R. Hart Chief Financial Officer 1973
Mr. Mark R. Ziebell J.D. VP, Gen. Counsel & Corp. Sec. 1964
Mr. Richard Richieri Chief Operations Officer 1965
Mr. Matthew Kwietniak Chief Commercial Officer NA
Dr. Shelley P. M. Fussey VP of Intellectual Property 1966
Ms. Tracy L. Kinjerski VP of Bus. Operations NA
Dr. Harold F. Dvorak M.D. Medical & Scientific Advisor NA
Prof. Alan J. Schroit Medical & Scientific Advisor NA
Prof. Rolf A. Brekken Ph.D. Medical & Scientific Advisor NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.